Literature DB >> 11290607

Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells.

J Hisatake 1, J O'Kelly, M R Uskokovic, S Tomoyasu, H P Koeffler.   

Abstract

The active form of vitamin D(3), 1,25(OH)(2)D(3), inhibits proliferation and induces differentiation of a variety of malignant cells. A new class of vitamin D(3) analogs, having 2 identical side chains attached to carbon-20, was synthesized and the anticancer effects evaluated. Four analogs were evaluated for their ability to inhibit growth of myeloid leukemia (NB4, HL-60), breast (MCF-7), and prostate (LNCaP) cancer cells. All 4 analogs inhibited growth in a dose-dependent manner. Most effective was 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3) (Gemini-19-nor), which has 2 side chains and removal of the C-19. Gemini-19-nor was approximately 40 625-, 70-, 23-, and 380-fold more potent than 1,25(OH)(2)D(3) in inhibiting 50% clonal growth (ED(50)) of NB4, HL-60, MCF-7, and LNCaP cells, respectively. Gemini-19-nor (10(-8) M) strongly induced expression of CD11b and CD14 on HL-60 cells (90%); in contrast, 1,25(OH)(2)D(3) (10(-8) M) stimulated only 50% expression. Annexin V assay showed that Gemini-19-nor and 1,25(OH)(2)D(3) induced apoptosis in a dose-dependent fashion. Gemini-19-nor (10(-8) M, 4 days) caused apoptosis in approximately 20% of cells, whereas 1,25(OH)(2)D(3) at the same concentration did not induce apoptosis. Gemini-19-nor increased in HL-60 both the proportion of cells in the G(1)/G(0) phase and expression level of p27(kip1). Moreover, Gemini-19-nor stimulated expression of the potential tumor suppressor, PTEN. Furthermore, other inducers of differentiation, all-trans-retinoic acid and 12-O-tetradecanoylphorbol 13-acetate, increased PTEN expression in HL-60. In summary, Gemini-19-nor strongly inhibited clonal proliferation in various types of cancer cells, especially NB4 cells, suggesting that further studies to explore its anticancer potential are warranted. In addition, PTEN expression appears to parallel terminal differentiation of myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290607     DOI: 10.1182/blood.v97.8.2427

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Change in the Ca2+ response to formyl peptide in HL-60 myeloblastic leukemia cells after the induction of their differentiation by MP-4 myelogenic peptide.

Authors:  E I Astashkin; N I Suvorov; A A Mikhailova; S V Grachev
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

Review 2.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

Review 4.  Vitamin D in the new millennium.

Authors:  Sunil J Wimalawansa
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

5.  Vitamin A facilitates enteric nervous system precursor migration by reducing Pten accumulation.

Authors:  Ming Fu; Yoshiharu Sato; Ariel Lyons-Warren; Bin Zhang; Maureen A Kane; Joseph L Napoli; Robert O Heuckeroth
Journal:  Development       Date:  2010-02       Impact factor: 6.868

6.  Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice.

Authors:  Wei Yu; Mark Cline; Larry G Maxwell; David Berrigan; Gustavo Rodriguez; Anni Warri; Leena Hilakivi-Clarke
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-21

Review 7.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

8.  Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.

Authors:  Young-Rae Lee; Hong-Nu Yu; Eun-Mi Noh; Jong-Suk Kim; Eun-Kyung Song; Myung-Kwan Han; Byeong-Soo Kim; Sung-Ho Lee; Jinny Park
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

9.  Novel Gemini vitamin D(3) analogs have potent antitumor activity.

Authors:  Tsuyako Saito; Ryoko Okamoto; Talin Haritunians; James O'Kelly; Milan Uskokovic; Hubert Maehr; Stanislaw Marczak; Pawel Jankowski; Riem Badr; H Phillip Koeffler
Journal:  J Steroid Biochem Mol Biol       Date:  2008-09-30       Impact factor: 4.292

10.  Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.

Authors:  Talin Haritunians; Saskia Gueller; James O'Kelly; Robert Ilaria; H Phillip Koeffler
Journal:  Oncol Rep       Date:  2008-11       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.